686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial

Laëtitia Mauge ,L Ben Dhia,Francisca Joly ,Isabelle Galy-Fauroux ,Y-A Vano ,R.t Elaidi ,Denis Maillet ,C Chevreau ,Christophe Tournigand ,Jessica Zucman–Rossi ,Diane Pannier ,Mostefa Bennamoun ,P Barthélémy ,S Bertil ,Gwénaëlle Gravis ,С Оудард ,M Gross-Goupil,Brigitte Laguerre ,Delphine Borchiellini ,Dominique Helley

doi:10.1016/j.annonc.2021.08.082

686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial

Laëtitia Mauge , L Ben Dhia + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.082

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 1	License type: publisher-specific-oa

Affiliation: Paris Cardiovascular Research Center, Université Paris Cité, Hôpital Européen Georges-Pompidou, Inserm, Assistance Publique – Hôpitaux de Paris, hpital europen georges pompidou

#Inhibitors #Predictive Biomarkers Of Efficacy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In the context of evolving therapeutic landscape in mRCC patients (pts) promoting IO and TKI combination, predictive biomarkers of efficacy are necessary. The role of circulating angiogenesis biomarkers (CABs) to predict response to IO has been assessed in the prospective BIONIKK trial.

Full Text